The 9th "International Symposium on Current Trends in Drug Discovery Research” inaugurated yesterday at CSIR-Central Drug Research Institute, Lucknow. Dr. Radha Rangrajan, Director CSIR-CDRI, Lucknow, ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
1d
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
The FDA has granted Fast Track designation to PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.
The Food and Drug Administration (FDA ... PP-01 is an investigational, oral cannabinoid-1 (CB1) partial agonist and GABAergic modulator that targets suppressed CB1 receptors and neurotransmitter ...
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show that viloxazine binds to and exhibits partial agonist activity at the ...
The Independent on MSN10d
People taking weight-loss drugs say they are losing their sight. Science is trying to figure out whyThere’s no direct link between vision loss and taking the weight loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, ...
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show that viloxazine binds to and exhibits partial agonist activity at the ...
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...
Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback